BT-101 (BOOST Cells)
Osteogenesis Imperfecta (moderate to severe, pediatric)
Phase 3 PreparationsActive
Key Facts
Indication
Osteogenesis Imperfecta (moderate to severe, pediatric)
Phase
Phase 3 Preparations
Status
Active
Company
About BOOST Pharma
BOOST Pharma is a clinical-stage biotech focused on a novel mesenchymal stem cell (MSC) therapy for Osteogenesis Imperfecta (OI), a severe rare pediatric disease with no approved therapy. The company has generated compelling clinical data showing over a 75% reduction in fracture rates and has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) in the US and EU. With a strengthened leadership team and recent investor funding, BOOST Pharma is preparing for a pivotal Phase III trial in the US and Europe to bring this potentially transformative treatment to market.
View full company profile